Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Effect of pretreatment with antifungal agents on clinical outcomes in fungal keratitis

Effect of pretreatment with antifungal agents on clinical outcomes in fungal keratitis CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY Sun, C. Q., Prajna, N., Krishnan, T., Rajaraman, R., Srinivasan, M., Raghavan, A., O'Brien, K. S., McLeod, S. D., Acharya, N. R., Rose-Nussbaumer, J., Mycotic Ulcer Treatment Trial Grp 2016; 44 (9): 763-767

Abstract

To determine if pretreatment with antifungal agents is predictive of worse clinical outcome in a fungal keratitis clinical trial.Non-pre-specified subgroup analysis of a randomized controlled trial in a tertiary hospital.Three hundred twenty-three fungal ulcer cases with an enrolment visual acuity of 20/40 to 20/400.The Mycotic Ulcer Treatment Trial I was a randomized, double-masked trial to determine the optimal treatment for filamentous fungal keratitis at the Aravind Eye Care System, India. Enrolled cases were randomized to receive topical natamycin or voriconazole. Prior antifungal medication use, dose and duration were collected at enrolment. A subgroup analysis was performed to determine if patients using natamycin or azoles at presentation have worse clinical outcomes compared with those who were not pretreated.Three-month visual acuity (primary), 3-month infiltrate or scar size, corneal perforation and/or transplant and re-epithelialization time.Of the 323 patients enrolled, 44% presented on an antifungal agent. Pretreated patients had larger mean baseline infiltrate size (P?

View details for DOI 10.1111/ceo.12794

View details for Web of Science ID 000392711900004

View details for PubMedID 27329780

View details for PubMedCentralID PMC5177485